Robert E. Waltermire - 16 Jan 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Senior VP, Chief Pharma Dev.
Signature
/s/ Brian J. Lynch**
Issuer symbol
MDGL
Transactions as of
16 Jan 2023
Net transactions value
$0
Form type
4
Filing time
18 Jan 2023, 19:00:26 UTC
Previous filing
24 Feb 2022
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Award $0 +5,667 $0.000000 5,667 16 Jan 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date.

Remarks:

**As attorney-in-fact for Reporting Person